Candidemia is the most common healthcare-associated invasive fungal infection, with an incidence of approximately 7–9 per 100,000 population in the U.S. and a crude in-hospital mortality of 25–46%. [1-4] It is a medical emergency requiring prompt antifungal therapy and source control.
The following figure illustrates the pathogenesis of invasive candidiasis, including routes of dissemination and metastatic complications:
1. History
- Candidemia often presents nonspecifically — fever unresponsive to broad-spectrum antibiotics is the most common presenting feature [2][5]
- Key HPI questions:
- Duration and pattern of fever, rigors, hemodynamic instability
- Recent hospitalization, ICU stay, surgery (especially abdominal)
- Presence of central venous catheters (CVCs), TPN, dialysis
- Prior antibiotic exposure (type, duration)
- History of injection drug use (accounts for ~10% of cases) [3-4]
- Immunosuppressive therapy, chemotherapy, transplant history
- Visual symptoms: blurred vision, floaters, eye pain (screen for endophthalmitis) [6]
- Bone/joint pain (metastatic seeding)
- Timing: median time from admission to candidemia diagnosis is 5 days (IQR 0–16) [3]
2. Alarm Features
- Septic shock — mortality approaches 100% without antifungal therapy within 24 hours and source control [2]
- Persistent candidemia (positive blood cultures >5 days on therapy) — suggests uncontrolled source, endovascular infection, or deep-seated focus [7]
- New visual symptoms (endophthalmitis complicates ~1.8–10% of cases) [6][8]
- New cardiac murmur (endocarditis found in ~11% of those who undergo echocardiography) [1]
- Signs of metastatic infection: vertebral osteomyelitis, hepatosplenic abscesses, renal abscesses [9]
- Hemodynamic instability, multiorgan failure, rising lactate
3. Medications
First-line treatment — Echinocandins (IDSA and ECMM/ISHAM strongly recommended): [2][7]
- Caspofungin: 70 mg IV load → 50 mg IV daily
- Micafungin: 100 mg IV daily
- Anidulafungin: 200 mg IV load → 100 mg IV daily
- Rezafungin: now also strongly recommended as first-line [7]
Alternatives
- Fluconazole 800 mg (12 mg/kg) load → 400 mg (6 mg/kg) daily — only for non-critically ill patients unlikely to have azole-resistant species [2]
- Liposomal amphotericin B 3–5 mg/kg daily — for azole- and echinocandin-resistant infections [2]
- Voriconazole — useful for step-down or when mold coverage is needed; preferred for ocular candidiasis [7]
Key medication considerations
- Echinocandins have poor intraocular penetration — switch to fluconazole or voriconazole if endophthalmitis is present [6-7]
- Step-down from echinocandin to oral fluconazole at 5–7 days if: hemodynamically stable, blood cultures cleared, susceptible isolate, source controlled, non-neutropenic, oral tolerated [2][7]
- Conventional amphotericin B deoxycholate is not recommended due to nephrotoxicity [7]
Medication contributors to candidemia risk
- Broad-spectrum antibiotics (especially glycopeptides, aminoglycosides, nitroimidazoles) [10]
- Corticosteroids, immunosuppressants [2]
4. Diet
- Total parenteral nutrition (TPN) is an independent risk factor for candidemia in both ICU and non-ICU settings [1][10]
- Transition to enteral nutrition when feasible to reduce risk
- No specific dietary triggers or restrictions for candidemia itself
- Adequate nutrition supports immune recovery
5. Review of Systems
- Constitutional: fever, rigors, malaise, night sweats
- Ophthalmologic: blurred vision, floaters, photophobia, eye pain
- Cardiovascular: new murmur, chest pain (endocarditis)
- Musculoskeletal: back pain, joint pain (osteomyelitis, septic arthritis)
- GI: abdominal pain (intra-abdominal abscess, hepatosplenic candidiasis)
- GU: flank pain, dysuria (renal abscess, candiduria)
- Neurologic: headache, altered mental status (CNS involvement)
- Skin: erythematous papular or nodular lesions (disseminated cutaneous candidiasis)
6. Collateral History and Family History
- Collateral from nursing/ICU staff regarding line care, duration of CVC placement, recent line changes
- Prior Candida colonization or infection history
- Recent surgical procedures, especially abdominal/GI
- History of injection drug use (emerging as a major risk factor, ~9–10% of cases) [3-4]
- Family history is generally not contributory, though genetic polymorphisms in innate immunity may increase susceptibility [9]
7. Risk Factors
Major risk factors (supported by prospective data): [1-4][10]
- Central venous catheter (present in 64–73% of cases)
- Broad-spectrum antibiotic exposure (present in 77–81% of cases)
- ICU admission (50–67% of candidemia occurs in ICU)
- Recent surgery, especially abdominal
- Total parenteral nutrition
- Renal replacement therapy / acute kidney injury
- Candida colonization at multiple sites
- Diabetes mellitus
- Malignancy (hematologic or solid organ, ~37–39% of cases)
- Neutropenia
- Solid organ transplant / hematopoietic cell transplant
- Injection drug use
- Severe hepatic disease, cirrhosis
- Burns
- COVID-19-related critical illness (associated with increased candidemia incidence 2020–2021) [4]
8. Differential Diagnosis
- Bacterial bloodstream infection / bacteremia — most common mimic; coexists with candidemia in ~20% of cases [11]
- Other invasive fungal infections (aspergillosis, mucormycosis) — especially in neutropenic or transplant patients
- Endocarditis (bacterial) — consider if persistent fever, new murmur
- Intra-abdominal abscess (bacterial) — especially post-surgical
- Drug fever — diagnosis of exclusion
- Catheter-related bloodstream infection (non-Candida) — similar risk factors
- Candida auris — emerging multidrug-resistant species, now nationally notifiable; accounted for 0.4% of U.S. cases [4]
Distinguishing features: Candidemia should be suspected in any hospitalized patient with fever unresponsive to antibiotics who has typical risk factors (CVC, TPN, broad-spectrum antibiotics, recent surgery) [2][7]
9. Past Medical History
- Prior episodes of candidemia or invasive candidiasis (risk of recurrence)
- Prior antifungal exposure (risk of resistance, especially echinocandin-resistant C. glabrata)
- Abdominal surgery history (anastomotic leak, peritonitis)
- Chronic liver disease / cirrhosis
- Malignancy and chemotherapy history
- Organ transplant history
- Diabetes mellitus
- Chronic kidney disease / dialysis
- HIV/AIDS or other immunodeficiency
10. Physical Exam
- Vitals: fever (may be absent in immunosuppressed), tachycardia, hypotension (septic shock)
- Eyes: dilated fundoscopic exam — fluffy white chorioretinal lesions (ocular candidiasis) [6]
- Cardiac: new murmur (endocarditis)
- Abdomen: tenderness, peritoneal signs (intra-abdominal candidiasis)
- Skin: erythematous papular/nodular lesions, especially on trunk and extremities (disseminated cutaneous candidiasis)
- Line sites: erythema, purulence, tenderness at CVC insertion sites
- Musculoskeletal: point tenderness over spine or joints (metastatic infection)
- Oral cavity: thrush (mucosal colonization)
11. Lab Studies
12. Imaging
- Echocardiography — recommended to evaluate for endocarditis; cardiac involvement found in ~11% of those examined [1][7]
- CT abdomen/pelvis — for suspected intra-abdominal candidiasis, hepatosplenic abscesses
- Abdominal ultrasound — hepatosplenic candidiasis (target lesions in liver/spleen), renal abscesses [14]
- CT/MRI spine — if vertebral osteomyelitis suspected
- Imaging is not routinely required for uncomplicated candidemia that clears promptly, but should be pursued for persistent candidemia or suspected deep-seated infection
13. Special Tests
- Dilated fundoscopic examination — IDSA strongly recommends within the first week of therapy for all nonneutropenic patients with candidemia. The AAO recommends examination only for symptomatic patients. Ocular candidiasis is found in ~6–19% of screened patients; endophthalmitis in ~1.8%. Screening sensitivity is higher when performed >7 days from first positive culture [2][6][8][15-16]
- Candida Score — clinical prediction rule incorporating surgery, TPN, multifocal colonization, and severe sepsis to identify ICU patients at risk [2]
- EQUAL Candida Score — measures guideline adherence; each point decrease associated with 8–9% increased mortality risk [1]
- MALDI-TOF mass spectrometry — enables rapid species identification from positive blood cultures [11]
14. ECG
- ECG is not a primary diagnostic tool for candidemia
- Obtain ECG if:
- Hemodynamic instability / septic shock
- Suspected endocarditis (conduction abnormalities, new heart block)
- Monitoring for QTc prolongation with azole antifungals (fluconazole, voriconazole)
- Baseline before initiating drugs with cardiac effects
15. Assessment
Candidemia is a life-threatening healthcare-associated infection with attributable mortality of 10–20% and crude mortality of 25–46%. [1-2][4]
Severity stratification
- Uncomplicated: candidemia without metastatic foci, hemodynamically stable, clears within 5 days
- Complicated: persistent candidemia, endophthalmitis, endocarditis, deep-seated organ involvement, septic shock
Species distribution (U.S. data): [4]
- C. albicans: 37%
- C. glabrata: 30% (higher fluconazole resistance)
- C. parapsilosis: 14% (catheter-associated)
- C. tropicalis, C. krusei: less common but clinically significant
- C. auris: 0.4% but emerging, often multidrug-resistant
Mortality predictors: increasing age, septic shock, APACHE II score, delayed antifungal therapy, CVC retention, C. tropicalis or C. glabrata species, immunosuppression, hypoalbuminemia [1-2][13]
16. Treatment Plan
Initial stabilization
- Hemodynamic resuscitation per sepsis protocols if shock present
- Start echinocandin empirically within 24 hours of clinical suspicion in high-risk patients with septic shock [2][7]
Definitive antifungal therapy
- Echinocandin as first-line (see dosing in Medications section) [2][7]
- Duration: 14 days from first negative blood culture (uncomplicated candidemia) [2][7]
- Step-down to oral fluconazole at day 5–7 if all prerequisites met [2][7]
Source control
- Remove all CVCs as soon as feasible — strongly recommended [17]
- Drain abscesses, manage anastomotic leaks or other surgical sources
Metastatic workup
- Dilated ophthalmologic exam within first week [2]
- Echocardiography [1][7]
- Follow-up blood cultures every 24–48 hours until clearance [2]
Ocular involvement
- fluconazole or voriconazole4–6 weeks[7]
17. Disposition
- Admission required for all patients with candidemia — this is an inpatient diagnosis requiring IV antifungal therapy and monitoring [2]
- ICU admission if septic shock, hemodynamic instability, or multiorgan dysfunction
- Observation/step-down once hemodynamically stable, cultures clearing, and transitioning to oral therapy
- Infectious diseases consultation — associated with improved survival (HR 0.81) [1]
- Ophthalmology consultation — for dilated fundoscopic exam [2]
- Cardiology/cardiac surgery — if endocarditis suspected or confirmed
18. Follow Up / Return Precautions
- Follow-up blood cultures every 24–48 hours until documented clearance [2]
- Repeat ophthalmologic exam if initial exam was negative but performed early (<7 days) [16]
- Outpatient follow-up within 1–2 weeks of discharge if transitioned to oral azole
- Monitor for relapse: recurrent fever, new symptoms of metastatic infection
- Return precautions: fever, rigors, visual changes, new rash, abdominal pain, back pain, hemodynamic instability
- Expected course: clinical improvement typically within 48–72 hours of appropriate therapy; blood cultures should clear within 3–5 days
- Long-term: address modifiable risk factors (CVC removal, antibiotic stewardship, transition off TPN when possible)
References
1. Guideline Adherence and Survival of Patients With Candidaemia in Europe: Results From the ECMM Candida III Multinational European Observational Cohort Study. — Hoenigl M, Salmanton-García J, Egger M, et al. The Lancet. Infectious Diseases. 2023.
2. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. — Pappas PG, Kauffman CA, Andes DR, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2016.
3. Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016. — Toda M, Williams SR, Berkow EL, et al. Morbidity and Mortality Weekly Report. Surveillance Summaries. 2019.
4. Population-Based Active Surveillance for Culture-Confirmed Candidemia - 10 Sites, United States, 2017-2021. — Jenkins EN, Gold JAW, Benedict K, et al. Morbidity and Mortality Weekly Report. Surveillance Summaries. 2025.
5. Invasive Candidiasis. — Kullberg BJ, Arendrup MC. The New England Journal of Medicine. 2015.
6. Eye Infections. — Durand ML, Barshak MB, Sobrin L. The New England Journal of Medicine. 2023.
7. Global Guideline for the Diagnosis and Management of Candidiasis: An Initiative of the ECMM in Cooperation With ISHAM and ASM. — Cornely OA, Sprute R, Bassetti M, et al. The Lancet. Infectious Diseases. 2025.
8. Prevalence of Ocular Candidiasis and Candida Endophthalmitis in Patients With Candidemia: A Systematic Review and Meta-Analysis. — Phongkhun K, Pothikamjorn T, Srisurapanont K, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2023.
9. Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Official American Thoracic Society Clinical Practice Guideline. — Epelbaum O, Marinelli T, Haydour QS, et al. American Journal of Respiratory and Critical Care Medicine. 2024.
10. Risk Factors for Candidemia: A Prospective Matched Case-Control Study. — Poissy J, Damonti L, Bignon A, et al. Critical Care. 2020.
11. Candida and Invasive Mould Diseases in Non-Neutropenic Critically Ill Patients and Patients With Haematological Cancer. — Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SC, Sorrell TC. The Lancet. Infectious Diseases. 2017.
12. American Society for Transplantation and Cellular Therapy Series, #6: Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients. — Neofytos D, Steinbach WJ, Hanson K, et al. Transplantation and Cellular Therapy. 2023.
13. Analysis of the Association of Neutrophil-to-Lymphocyte Ratio, MPV-to-platelet Ratio, and Clinical Risk Factors for Mortality in ICU Patients With Candidemia: A 10-Year Retrospective Analysis. — Ödemiş İ, Arkalı E, Serin Senger S, et al. A BMC Infectious Diseases. 2025.
14. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
15. American Academy of Ophthalmology Recommendations on Screening for Endogenous Candida Endophthalmitis. — Breazzano MP, Bond JB, Bearelly S, et al. Ophthalmology. 2022.
16. Do Patients With Candidemia Need an Ophthalmologic Examination?. — Lehman A, Tessier KM, Sattarova V, et al. Open Forum Infectious Diseases. 2024.
17. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. — Mermel LA, Allon M, Bouza E, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2009.